Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
ExeVir Bio from Gent, company number BE0750495334, closed financial year 2025 with a result of € -1.9 million after tax. For that financial year ExeVir Bio recorded a gross margin of € -1.2 million and equity of € 3.7 million. Compared with financial year 2024, the result moved from € -4.8 million to € -1.9 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
€ 3.7 million
▼ 35% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.9 million
▲ 60 % less loss than in 2024
Profit after tax over the fiscal year.
€ 925,562
▼ 71% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -12 million.
People and assets in 2025
1.8
▼ 7.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 411,091
▼ 69% vs 2024
€ 228,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 477
▼ 87% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 32,375
Loans from banks and other lenders, long and short.
€ 53,447
▼ 92% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 134
▼ € 101,391 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 11,913,017 | € 2,271,646 | € 939,421 | € -1,174,457 | ▼ € 2.1 million |
| Profit after taxes | € -1,731,925 | € -5,261,329 | € -4,822,921 | € -1,943,989 | ▲ € 2.9 million |
| Equity | € 15,700,791 | € 10,439,462 | € 5,616,541 | € 3,672,552 | ▼ 35% |
| Total debts | € 3,077,906 | € 2,197,740 | € 916,044 | € 85,956 | ▼ 91% |
| Cash | € 11,015,112 | € 3,407,696 | € 3,191,055 | € 925,562 | ▼ 71% |
| Retained profit | € 0 | € -5,261,329 | € -10,084,250 | € -12,028,240 | ▼ € 1.9 million |
| Bank debt | € 0 | € 0 | € 32,375 | € 32,375 | |
| Balance sheet total | € 18,778,697 | € 12,637,202 | € 6,532,585 | € 3,758,508 | ▼ 42% |
| Employees (FTE) | 10.1 | 8.3 | 9.1 | 1.8 | ▼ 7.3 |
Key figures of ExeVir Bio, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ExeVir Bio?
What happened at ExeVir Bio in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Stefaan HEYLEN stepped down as director. NBB
- Erika WHITTAKER stepped down as director. NBB
- Halina NOVAK stepped down as director. NBB
- Jérôme VAN BIERVLIET stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.9 million. Source: NBB ↗
- Stefaan HEYLEN became a director. NBB
- Jeanne BOLGER stepped down as director. NBB
- SPARAXIS NV stepped down as director. NBB
In short
From € 1.7 million loss in 2022 to € 1.9 million loss in 2025.
On average € 103,200 of value added per employee in 2024.
Management
The stake of Fund+, UCB BIOPHARMA, FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ, Vives Inter-University Fund comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ExeVir BioThe shares are held by Fund+ (19%), UCB BIOPHARMA (17.9%), FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ (13.4%) and Vives Inter-University Fund (4.5%).
Directors
According to the 2025 annual accounts
Stefaan HEYLEN
Director
since 2026 · until 2032
Jeanne BOLGER
Director
since 2022 · until 2026
Director · represented by Caroline Thielen
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International, Ateliers Pierre Cerfontaine, Floridienne, Fonderies J. Marichal Ketin et Cie, JUNGLING, MEBF +224 more
since 2020 · until 2026
Kenneth BONHEURE
Director
since 2024 · until 2026
Michael GARRETT
Managing director
since 2024 · until 2026
Erika WHITTAKER
Director
since 2026 · until 2032
Halina NOVAK
Director
since 2026 · until 2032
Jérôme VAN BIERVLIET
Director
since 2026 · until 2032
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 94
9052 Gent
Boulevard de Patience et Beaujonc 3 box 14
4000 Liège
Active since 1 January 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →ILiAD Biotechnologies
€ 1.4 million gross margin · 2025
Zomagen Biosciences Belgium
€ 1.2 million gross margin · 2025
AnimAb
€ 28,596 gross margin · 2025
Protealis
€ 1.1 million gross margin · 2025
YAKULT HONSHA EUROPEAN RESEARCH CENTER FOR MICROBIOLOGY
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0750.495.334
- VAT number
- BE 0750.495.334
- Registered office
- Technologiepark-Zwijnaarde 94, 9052 Gent
- Names & denominations
- ExeVir Bio · ExeVir
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 July 2020
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied